SB Management’s LENZ Therapeutics LENZ Stock Holding History

SB Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-141,915	Closed	-$30.5M	–	37
2021 Q2	$30.5M	Buy	+141,915	New	+$24.7M	0.36%	18

Other funds holding LENZ

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SB Management's LENZ Position: Q3 2021 in Review

SB Management sold out of LENZ Therapeutics (LENZ) in Q3 2021, closing a stake of 141,915 shares — an estimated $30.5M sold.

SB Management first reported a position in LENZ in Q2 2021 and held it in 1 quarter. The position peaked at $30.5M in Q2 2021. 60 funds tracked by Wall St. Rank hold LENZ as of Q3 2021.

SB Management reported no remaining LENZ Therapeutics position as of Q3 2021 after selling out during the quarter.
SB Management sold 141,915 LENZ Therapeutics shares in Q3 2021, an estimated $30.5M.
SB Management first reported a position in LENZ Therapeutics in Q2 2021 and held it in 1 quarter.
SB Management's LENZ Therapeutics position peaked at $30.5M in Q2 2021.
60 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2021.

Based on SB Management's 13F filing for Q3 2021, filed 12 Nov 2021.